Nine Masts Capital’s Abivax ABVX Stock Holding History

Nine Masts Capital’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$196K	Buy	+93	New	+$10.5K	0.02%	140

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nine Masts Capital's ABVX Position: Q2 2026 in Review

Nine Masts Capital reduced its Abivax (ABVX) stake by 87% in Q2 2026, selling an estimated $736K and leaving 998 shares worth $133K. The position accounts for 0.01% of the portfolio, ranked #151.

Nine Masts Capital first reported a position in ABVX in Q4 2025 and has held it in 3 quarters since. The position peaked at $835K in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Nine Masts Capital held 998 shares of Abivax worth $133K as of Q2 2026.
Nine Masts Capital sold 6,502 Abivax shares in Q2 2026, an estimated $736K.
Abivax made up 0.01% of Nine Masts Capital's portfolio in Q2 2026, its #151 holding.
Nine Masts Capital first reported a position in Abivax in Q4 2025 and has held it in 3 quarters since.
Nine Masts Capital's Abivax position peaked at $835K in Q1 2026.
302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.